Ideaya Biosciences Inc (IDYA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ideaya Biosciences Inc stock (IDYA) is currently trading at $31.39. Ideaya Biosciences Inc PS ratio (Price-to-Sales) is 12.26. Analyst consensus price target for IDYA is $50.00. WallStSmart rates IDYA as Sell.
- IDYA PE ratio analysis and historical PE chart
- IDYA PS ratio (Price-to-Sales) history and trend
- IDYA intrinsic value — DCF, Graham Number, EPV models
- IDYA stock price prediction 2025 2026 2027 2028 2029 2030
- IDYA fair value vs current price
- IDYA insider transactions and insider buying
- Is IDYA undervalued or overvalued?
- Ideaya Biosciences Inc financial analysis — revenue, earnings, cash flow
- IDYA Piotroski F-Score and Altman Z-Score
- IDYA analyst price target and Smart Rating
Ideaya Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Ideaya Biosciences Inc (IDYA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Ideaya Biosciences Inc (IDYA) Key Strengths (3)
Revenue surging 55.40% year-over-year
110.71% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Ideaya Biosciences Inc (IDYA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.3x annual revenue
Fairly priced relative to book value
Supporting Valuation Data
Ideaya Biosciences Inc (IDYA) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 55.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (12.26), Price/Book (2.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -10.90%, Operating Margin at -870.00%, Profit Margin at -52.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -10.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 55.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IDYA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IDYA's Price-to-Sales ratio of 12.26x trades at a deep discount to its historical average of 104.77x (0th percentile). The current valuation is 97% below its historical high of 446.85x set in Nov 2025, and 0% above its historical low of 12.26x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~213.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ideaya Biosciences Inc (IDYA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ideaya Biosciences Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 219M with 55% growth year-over-year. The company is currently unprofitable, posting a -52.0% profit margin.
Key Findings
Revenue growing at 55% YoY, reaching 219M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 113M in cash.
The company is unprofitable with a -52.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -91M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Ideaya Biosciences Inc maintain 55%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ideaya Biosciences Inc.
Bottom Line
Ideaya Biosciences Inc is a high-conviction growth story with revenue accelerating at 55% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -52.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(8 last 3 months)
| Insider | Type | Shares |
|---|---|---|
STEIN, JEFFREY Director | Buy | +50,000 |
Data sourced from SEC Form 4 filings
Last updated: 10:02:26 AM
About Ideaya Biosciences Inc(IDYA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.